Genevieve Rail – “lead developer” of HPV vaccines opposes it

Genevieve Rail

Here we go again. We recently wrote about Diane Harper, another “lead developer” of the HPV vaccines, who has a rather complicated view on HPV vaccines. She makes disparaging remarks about the vaccine, yet her peer reviewed publications are generally favorable to the HPV vaccine. Genevieve Rail, a kinesiology researcher at Concordia University in Montreal, Quebec, Canada is the next one being pushed by anti-vaccine activists.

Outrageous claims are made about Genevieve Rail’s expertise with HPV vaccines, like Gardasil. And she helps with the claims by making outlandish comments about the vaccine:

“I’m sort of raising a red flag, out of respect for what I’ve found in my own study, and for the despair of parents who had totally perfect 12-year-olds who are now in their beds, too tired to go to school. Yes, we’re going against the grain, and we are going against those who are believed, i.e. doctors and nurses and people in public health.”

So here we go again, another darling of the anti-vaccine world. Time to look into who Genevieve Rail is. And does she have any standing in the scientific knowledge about the HPV vaccine. Continue reading “Genevieve Rail – “lead developer” of HPV vaccines opposes it”

Measles vaccine may be more effective if administered slightly later

A new research study published in Clinical Infectious Diseases has demonstrated that the MMR vaccine (measles, mumps and rubella) was more effective in teenagers who received their first dose of the two dose series at 15 months rather than at 12 months. The study was based on a more than 750 cases in 2011 of measles were reported in Quebec, Canada. Those individuals had received the routine 2-dose measles immunization schedule which is given at 12 and 18 months of age, which had been in effect in Quebec since 1996. This study assessed the effectiveness of this schedule during this outbreak that occurred during high school. Continue reading “Measles vaccine may be more effective if administered slightly later”